Literature DB >> 3654953

Preliminary antimicrobial susceptibility interpretive criteria for cefetamet (Ro 15-8074) and cefteram (Ro 19-5247) disk tests.

R N Jones1, A L Barry.   

Abstract

Preliminary interpretive zone criteria were calculated for cefetamet (Ro 15-8074) and cefteram (Ro 19-5247) by using 10- and 30-micrograms disks and three possible MIC susceptibility breakpoints. Absolute interpretive agreement between MICs and zone size criteria ranged from 91.8 to 97.2%. Very major errors (false susceptibility) were less than or equal to 1.2% for both cephalosporin disk tests. Morganella morganii strains appeared to produce the highest rates of very major interpretive errors with cefetamet disks.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3654953      PMCID： PMC269336          DOI： 10.1128/jcm.25.9.1796-1799.1987

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  10 in total

1.  Susceptibility tests of anaerobic bacteria: statistical and clinical considerations.

Authors:  C M Metzler; R M DeHaan
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

2.  Antimicrobial activity of Ro 15-8074, active metabolite of a new oral cephalosporin (Ro 15-8075), against 7,775 recent clinical isolates.

Authors:  R N Jones; P C Fuchs; A L Barry; L W Ayers; E H Gerlach; T L Gavan
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

3.  In vitro activity of Ro 15-8074, a new oral cephalosporin, against Neisseria gonorrhoeae.

Authors:  W S Ng; P Y Chau; Y K Leung; P C Wong
Journal:  Antimicrob Agents Chemother       Date:  1985-09       Impact factor: 5.191

4.  In-vitro activity of Ro-15-8074, a new oral cephalosporin.

Authors:  M Peeters; P Piot
Journal:  J Antimicrob Chemother       Date:  1985-10       Impact factor: 5.790

5.  In vitro and in vivo antibacterial properties of FK 027, a new orally active cephem antibiotic.

Authors:  T Kamimura; H Kojo; Y Matsumoto; Y Mine; S Goto; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

6.  In vitro activity and beta-lactamase stability of two oral cephalosporins, ceftetrame (Ro 19-5247) and cefetamet (Ro 15-8074).

Authors:  H C Neu; N X Chin; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

7.  In vitro activities of Ro 19-5247 and Ro 15-8074, new oral cephalosporins.

Authors:  R J Fass; V L Helsel
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

8.  Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency.

Authors:  D R Guay; R C Meatherall; G K Harding; G R Brown
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

9.  Cefixime disk susceptibility test criteria.

Authors:  P C Fuchs; A L Barry; R N Jones
Journal:  J Clin Microbiol       Date:  1986-10       Impact factor: 5.948

10.  In vitro activity of Ro 15-8074 and Ro 19-5247, two orally administered cephalosporin metabolites.

Authors:  R Wise; J M Andrews; L J Piddock
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191
  10 in total
  13 in total

1.  Interpretive criteria for disk diffusion tests using 5-microgram cefdinir disks with rapidly growing clinical isolates.

Authors:  R N Jones; M E Erwin; B B Gooding
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

2.  Use of a predictor panel for development of a new disk for diffusion tests with cefoperazone-sulbactam.

Authors:  P A Bradford; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

3.  Preliminary disk diffusion susceptibility testing criteria for cefdaloxime (RU29246, HR-916 metabolite), a new orally administered cephalosporin.

Authors:  R N Jones; M E Erwin
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948

4.  Antimicrobial activity, spectrum, and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SCH 39720), a new orally administered cephalosporin.

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

5.  Disk diffusion susceptibility testing and broth microdilution quality control guidelines for BMY-28100, a new orally administered cephalosporin.

Authors:  R N Jones; A L Barry
Journal:  J Clin Microbiol       Date:  1987-11       Impact factor: 5.948

Review 6.  Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  H M Bryson; R N Brogden
Journal:  Drugs       Date:  1993-04       Impact factor: 9.546

7.  Antimicrobial activity and disk diffusion susceptibility testing of U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807).

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

8.  Predictive accuracy of disk diffusion test for Proteus vulgaris and Providencia species against five newer orally administered cephalosporins, cefdinir, cefetamet, cefprozil, cefuroxime, and loracarbef.

Authors:  D J Biedenbach; R N Jones
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

9.  Interpretive accuracy of the disk diffusion method for testing newer orally administered cephalosporins against Morganella morganii.

Authors:  D J Biedenbach; R N Jones; M E Erwin
Journal:  J Clin Microbiol       Date:  1993-10       Impact factor: 5.948

10.  Cefetamet pivoxil: bacteriostatic and bactericidal activity of the free acid against 355 gram-negative rods.

Authors:  P Hohl; A von Graevenitz; J Zollinger-Iten
Journal:  Infection       Date:  1988 May-Jun       Impact factor: 3.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.